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A) Comparing RNA-seq read coverage for a 
portion of the CDK10 gene shows that some 
introns are more frequently retained in the 
tumor sample than the adjacent normal tissue. 
B) For each individual, the number of introns 
retained in the tumor sample (y-axis) is plotted 
against the number of introns retained in the 
matched normal sample (x-axis). Aggregating 
patients, most tumors showed much more 
frequent intron retention (left, middle), while 
breast cancer was the exception where normal 
tissue exhibited more common intron retention 
(right). 
 






Alternative splicing of specific genes can contribute to cancer initiation, progression, and 
metastasis.  With the advent of cancer genome sequencing, it was discovered that many tumor 
types contain high frequencies of somatic mutations affecting components of the RNA splicing 
machinery.  Additional evidence suggested that common RNA processing differences might 
distinguish between cancer and normal cells, but had not been systematically tested.  To evaluate 
this question, Drs. Heidi Dvinge and Robert Bradley in the Public Health Sciences and Basic 
Sciences Divisions performed a genome-wide search for signals of abnormal cancer-associated 
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splicing.  As recently reported in Genome Medicine, the authors found that abnormal RNA splicing is 
a common characteristic of most cancers, even when the RNA splicing machinery appears 
unaltered.   
Genes are made up of protein-encoding exons interspersed with introns.  Normally, DNA is 
transcribed into RNA and then modified through a process that only retains the genetic information 
from the exons.  In this process, the cellular splicing machinery excises the introns out of the RNA 
copy and joins the ends of exons together.  "One of the surprising findings from the large-scale 
cancer genomics effort in the last few years has been the high frequency of mutations in the RNA 
processing machinery," said lead author Dr. Dvinge.  Errors in this process can result in the retention 
of introns, potentially leading to abnormal protein products with unknown consequences.   
To evaluate for systematic differences in RNA splicing, the authors utilized the comprehensive 
transcriptome data available from The Cancer Genome Atlas (TCGA).  This involved comparing 
patterns of RNA splicing between 800 tumor and patient-matched normal control samples, and 
across 16 distinct cancer types.  These cancers included 15 solid tumors as well as one liquid tumor 
(acute myeloid leukemia).  Using RNA-seq data from TCGA, for each tumor-normal pair the authors 
identified introns that were differentially retained between the samples (see figure).  These 
differences in intron retention were quantified and then compared among and across cancer 
types.  Said Dr. Dvinge, "we found that abnormal RNA splicing is a common feature of a wide range 
of primary tumors, even in the absence of DNA mutations or other obvious changes to the RNA 
processing machinery." 
Notably, 15 of the 16 cancer types showed a strong enrichment for increased retention of alternative 
introns within the tumor compared to the adjacent normal control tissue.  The one exception was 
breast cancer, which actually showed the opposite pattern.  The authors found that the majority of 
these retained introns were either specific to a particular cancer, or were found at low frequencies in 
multiple cancers.  At the same time, a handful of retained introns were shared across most cancer 
types, mostly within genes encoding RNA splicing and export factors.  These results suggest that the 
RNA splicing process may be commonly dysregulated in cancer, which may be useful for 
differentiating normal versus cancerous cells.   
While this study demonstrates that intron retention is a common occurrence in many tumor types, 
the functional consequences of this phenomenon remain to be explored.  "It remains to be seen 
whether the intron-containing transcripts are dead-end cellular products, or whether they contribute 
to the cancer proteome," said Dr. Dvinge.  "Regardless, analyzing the dysregulated RNA splicing 
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events may help us to unravel why small molecules that inhibit splicing also have anti-tumor activity, 
or help design novel therapies targeting tumor cells." 
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